Hepalink Pharmaceutical Group, which is deeply involved in the vortex of telecom fraud, recently released its 2023 annual performance forecast, and is expected to lose 6$4.7 billion to $92.4 billion yuan, of which the impact of telecom fraud cases on the year's performance is expected to be between 9 million euros and 11.74 million euros. Hepalink also disclosed the circumstances of the telecom fraud case.
It is reported that Hepalink only disclosed these circumstances after receiving an inquiry letter from the Shenzhen Stock Exchange. Hepalink is the world's largest heparin API provider, and Hepalink believes that the decline in performance is caused by four factors.
First, in 2023, the world's major heparin companies have generally slowed down the pace of production, and the company's API business has also been greatly impacted, and the preparation business in non-European and American overseas markets has also shown a certain degree of decline. Second, the selling price of heparin products has declined sharply since the fourth quarter of 2023, and some heparin products in the company's heparin industry chain inventory showed signs of impairment in the fourth quarter of 2023. Third, the company's investment losses further expanded due to the increase in the valuation of the associate company HighTide at the time of listing on the Hong Kong Stock Exchange, which led to further changes in the fair value of financial liabilities in the fourth quarter. Fourth, the Italian telecom fraud case caused losses.
However, the market questioned that Hepalink's illegal payment of money only through email believing in the acquisition and merger did not comply with the management rules of well-known domestic pharmaceutical companies, and whether there was a possibility of related party transactions or benefit transfer.
The reporter called Hepalink, but as of press time, Hepalink has not responded.